Join to View Full Profile
Elm and Carlton StBuffalo, NY 14263
Phone+1 716-845-2300
Fax+1 716-845-1322
Dr. Griffiths is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Elizabeth Griffiths is a highly experienced oncologist specializing in hematologic oncology based in Buffalo, NY. She completed both her residency in Internal Medicine and fellowship in Hematology and Medical Oncology at Johns Hopkins University after graduating from the University of North Carolina at Chapel Hill School of Medicine. Her expertise extends to procedures such as bone marrow biopsy and managing platelet disorders, primary myelofibrosis, essential thrombocytosis, and aplastic anemia. Dr. Griffiths has carried out substantial research in her field, publishing numerous articles in esteemed journals like Cancer, Blood Advances, The Lancet Haematology, and Current Opinion in Hematology, and serves as the Principal Investigator for several clinical trials investigating treatments for Acute Myeloid Leukemia.
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2005 - 2008- Johns Hopkins UniversityResidency, Internal Medicine, 2002 - 2005
University of North Carolina at Chapel Hill School of MedicineClass of 2002
Certifications & Licensure
NY State Medical License 2009 - 2027
MD State Medical License 2005 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Lenalidomide and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2011 Feb 07
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Start of enrollment: 2013 Jul 30
- Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML) Start of enrollment: 2021 Feb 09
- Join now to see all
Publications & Presentations
PubMed
- Platelet glycosylation in myelodysplastic syndromes correlates with disease severity.Katelyn E Rosenbalm, Tin Long Wong, Donny Hoang, Valerie L Andersen, George Steinhardt
Blood Advances. 2025-09-23 - 1 citationsEfficacy and safety of oral decitabine/cedazuridine in the chronic myelomonocytic leukaemia subpopulations from phase 2 and 3 studies.Michael R Savona, Olatoyosi Odenike, Gail J Roboz, Harshad Amin, Amy E DeZern
British Journal of Haematology. 2025-08-01 - Checkpoint immunotherapy is associated with preferential activation of tumor antigen-specific CD4T cells in MDS.Elizabeth A Griffiths, Pragya Srivastava, Eduardo Cortes Gomez, Junko Matsuzaki, Kunle Odunsi
Blood Neoplasia. 2025-08-01
Abstracts/Posters
- Phase II Study of Oral Rigosertib Combined with Azacitidine (AZA) As First Line Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS)Elizabeth A. Griffiths, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- De Novo and Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome: Similarities and Differences in SNP-Array Detected Chromosomal Aberrations in Pre-Tran...Elizabeth A. Griffiths, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Na¥ve (TN) AML Unfit for Intensive Chemothe...Elizabeth A. Griffiths, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- Acute Myeloid Leukemia: Moving Beyond 7+360th American Society of Hematology Annual Meeting - 12/1/2018
- Acute Myeloid Leukemia: Moving Beyond 7+460th American Society of Hematology Annual Meeting - 12/1/2018
- Long Term Results of a Randomized Phase 2 Dose-Response Study of Guadecitabine, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediat...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Roswell Park Hematologists Present New Research on FLT3 Inhibitors, CART-19 at ASH Annual MeetingDecember 11th, 2021
First Advance in MDS for Decade: Luspatercept for AnemiaApril 6th, 2020
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
